TY - JOUR
AU - Jenkins C.
AU - Peters M.
AU - Gibson P.
AU - Simpson J.
AU - Yang I.
AU - Upham J.
AU - Reynolds P.
AU - Hodge S.
AU - James A.
AU - Jia G.
AU - Holweg C.
AB - <p>
BACKGROUND: Periostin levels are associated with airway eosinophilia and are suppressed by corticosteroid treatment in asthma. This study sought to determine the relationship between serum and sputum periostin, airway inflammatory phenotype and asthma control. METHODS: Adults with poorly-controlled asthma (n = 83) underwent a clinical assessment, sputum induction and blood sampling. Dispersed sputum was used for a differential cell count and periostin assessment (ELISA). Serum periostin was determined by the Elecsys(R) immunoassay. RESULTS: Periostin levels were significantly higher in serum (median (IQR) of 51.6 (41.8, 62.6) ng/mL) than in sputum (1.1 (0.5, 2.0) ng/mL) (p &lt; 0.001). Serum and sputum periostin were significantly higher in patients with eosinophilic asthma (n = 37) compared with non-eosinophilic asthma. Both serum and sputum periostin levels were significantly associated with proportion of sputum eosinophils (r = 0.422, p &lt; 0.001 and r = 0.364, p = 0.005 respectively) but were not associated with asthma control. In receiver operator characteristic curve analysis, the area under the curve (AUC) for serum periostin (n = 83) was 0.679, p = 0.007. Peripheral blood eosinophils assessed in 67 matched samples, had a numerically greater AUC of 0.820 compared with serum periostin, p = 0.086 for the detection of eosinophilic asthma. CONCLUSION: In poorly-controlled asthma, sputum and serum periostin levels are significantly related to sputum eosinophil proportions while their ability to predict the presence of eosinophilic asthma is modest.
</p>

AD - Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Level 2, West Wing, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia. jodie.simpson@newcastle.edu.au.<br/>Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, NSW, Australia. jodie.simpson@newcastle.edu.au.<br/>School of Medicine, The University of Queensland, Brisbane, QLD, Australia.<br/>Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia.<br/>Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia.<br/>Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia.<br/>Lung Research Laboratory, Hanson Institute, Adelaide, SA, Australia.<br/>Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.<br/>School of Medicine and Pharmacology, The University of Western Australia, Crawley, WA, Australia.<br/>Respiratory Trials, The George Institute for Global Health, Sydney, NSW, Australia.<br/>Department of Thoracic Medicine, Concord General Hospital, Concord, NSW, Australia.<br/>Australian School of Advanced Medicine, Macquarie University, Sydney, NSW, Australia.<br/>Genentech Inc, South San Francisco, CA, USA.<br/>Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Level 2, West Wing, Lot 1 Kookaburra Circuit, New Lambton Heights, NSW, 2305, Australia.<br/>Priority Research Centre for Asthma and Respiratory Disease, The University of Newcastle, Newcastle, NSW, Australia.<br/>Woolcock Institute of Medical Research, Glebe, NSW, Australia.
AN - 27130294
BT - BMC Pulmonary Medicine
C2 - PMC4851782
DP - NLM
ET - 2016/05/01
LA - eng
LB - AUS<br/>RSP<br/>FY16
M1 - 1
N1 - Simpson, Jodie L<br/>Yang, Ian A<br/>Upham, John W<br/>Reynolds, Paul N<br/>Hodge, Sandra<br/>James, Alan L<br/>Jenkins, Christine<br/>Peters, Matthew J<br/>Jia, Guiquan<br/>Holweg, Cecile T J<br/>Gibson, Peter G<br/>England<br/>BMC Pulm Med. 2016 Apr 30;16(1):67. doi: 10.1186/s12890-016-0230-4.
N2 - <p>
BACKGROUND: Periostin levels are associated with airway eosinophilia and are suppressed by corticosteroid treatment in asthma. This study sought to determine the relationship between serum and sputum periostin, airway inflammatory phenotype and asthma control. METHODS: Adults with poorly-controlled asthma (n = 83) underwent a clinical assessment, sputum induction and blood sampling. Dispersed sputum was used for a differential cell count and periostin assessment (ELISA). Serum periostin was determined by the Elecsys(R) immunoassay. RESULTS: Periostin levels were significantly higher in serum (median (IQR) of 51.6 (41.8, 62.6) ng/mL) than in sputum (1.1 (0.5, 2.0) ng/mL) (p &lt; 0.001). Serum and sputum periostin were significantly higher in patients with eosinophilic asthma (n = 37) compared with non-eosinophilic asthma. Both serum and sputum periostin levels were significantly associated with proportion of sputum eosinophils (r = 0.422, p &lt; 0.001 and r = 0.364, p = 0.005 respectively) but were not associated with asthma control. In receiver operator characteristic curve analysis, the area under the curve (AUC) for serum periostin (n = 83) was 0.679, p = 0.007. Peripheral blood eosinophils assessed in 67 matched samples, had a numerically greater AUC of 0.820 compared with serum periostin, p = 0.086 for the detection of eosinophilic asthma. CONCLUSION: In poorly-controlled asthma, sputum and serum periostin levels are significantly related to sputum eosinophil proportions while their ability to predict the presence of eosinophilic asthma is modest.
</p>

PY - 2016
SN - 1471-2466 (Electronic)<br/>1471-2466 (Linking)
EP - 67
T2 - BMC Pulmonary Medicine
TI - Periostin levels and eosinophilic inflammation in poorly-controlled asthma
VL - 16
Y2 - FY16
ER -